search button

EpCAM-independent capture of circulating tumor cells with a ‘universal CTC-chip’

  • Authors:
    • Yasuhiro Chikaishi
    • Kazue Yoneda
    • Takashi Ohnaga
    • Fumihiro Tanaka

  • View Affiliations

  • Published online on: November 8, 2016     https://doi.org/10.3892/or.2016.5235
  • Pages: 77-82
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Capture of circulating tumor cells (CTCs), which are shed from the primary tumor site and circulate in the blood, remains a technical challenge. CellSearch® is the only clinically approved CTC detection system, but has provided only modest sensitivity in detecting CTCs mainly because epithelial cell adhesion molecule (EpCAM)-negative tumor cells may not be captured. To achieve more sensitive CTC‑capture, we have developed a novel microfluidic platform, a ʻCTC-chipʼ comprised of light-curable resins that has a unique advantage in that any capture antibody is easily conjugated. In the present study, we showed that EpCAM-negative tumor cells as well as EpCAM-positive cells were captured with the novel ʻuniversal CTC-chipʼ as follows: i) human lung cancer cells (PC-9), with strong EpCAM expression, were efficiently captured with the CTC-chip coated with an anti-EpCAM antibody (with an average capture efficiency of 101% when tumor cells were spiked in phosphate‑buffered saline (PBS) and 88% when spiked in blood); ii) human mesothelioma cells (ACC-MESO-4), with no EpCAM expression but with podoplanin expression, were captured with the CTC-chip coated with an anti-podoplanin antibody (average capture efficiency of 78% when tumor cells were spiked in PBS and 38% when spiked in blood), whereas ACC-MESO-4 cells were not captured with the CTC-chip coated with the anti-EpCAM antibody. These results indicate that the novel ʻCTC-chipʼ can be useful in sensitive EpCAM-independent detection of CTCs, which may provide new insights into personalized medicine.
View Figures
View References

Related Articles

Journal Cover

January-2017
Volume 37 Issue 1

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 3.8
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 8.5
  • CiteScore Rank: Q1: #74/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.719
  • SCImago Journal Rank (SJR): 0.864
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Chikaishi Y, Yoneda K, Ohnaga T and Tanaka F: EpCAM-independent capture of circulating tumor cells with a ‘universal CTC-chip’. Oncol Rep 37: 77-82, 2017.
APA
Chikaishi, Y., Yoneda, K., Ohnaga, T., & Tanaka, F. (2017). EpCAM-independent capture of circulating tumor cells with a ‘universal CTC-chip’. Oncology Reports, 37, 77-82. https://doi.org/10.3892/or.2016.5235
MLA
Chikaishi, Y., Yoneda, K., Ohnaga, T., Tanaka, F."EpCAM-independent capture of circulating tumor cells with a ‘universal CTC-chip’". Oncology Reports 37.1 (2017): 77-82.
Chicago
Chikaishi, Y., Yoneda, K., Ohnaga, T., Tanaka, F."EpCAM-independent capture of circulating tumor cells with a ‘universal CTC-chip’". Oncology Reports 37, no. 1 (2017): 77-82. https://doi.org/10.3892/or.2016.5235